Evidence map›Paper›PMID 41163992›Full record

ArticleNeurosurgery practice2025

Male Breast Cancer Brain Metastases: Genetic Profiles and Radiosurgery Outcomes.

Yusuke S Hori, Paul M Harary, Aroosa Zamarud, Ahed H Kattaa, Amit R L Persad, Armine Tayag, Louisa Ustrzynski, Sara C Emrich, David J Park, Gordon Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurosurgery practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yusuke S HoriDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.
Paul M HararyDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.
Aroosa ZamarudDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.
Ahed H KattaaDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.
Amit R L PersadDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.
Armine TayagDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.
Louisa UstrzynskiDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.
Sara C EmrichDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.
David J ParkDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.
Gordon LiDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.
Steven D ChangDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.ORCID https://orcid.org/0000-0002-4315-681X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesMale breast cancer (MBC) is very rare, and previous reports of brain metastases (BM) from MBC are limited. To date, the genetic characteristics of MBC with BM have not been explored. In addition, there is only a single case report documenting the use of stereotactic radiosurgery (SRS) for MBC BM. The aim of this study was to summarize genetic alterations associated with BM in patients with MBC and evaluate the safety and efficacy of SRS in this population.

methodsFour male patients with a total of 20 MBC BMs treated with SRS were retrospectively reviewed. We defined treatment response as complete response, partial response, stable disease, and local progression (LP), per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The Kaplan-Meier method was used to estimate cumulative incidence rate of LP.

resultsThe median overall survival was 16.3 months (95% confidence interval: 1.4-31.3 months). The mean age at treatment was 59 years (IQR: 56-60.5 years). Three patients had estrogen receptor-positive lesions, whereas one patient had triple-negative disease. Three patients had notable pathogenic alterations (including in

conclusionThis is the first report of genetic profiling of MBC with BM and excellent SRS outcomes. The receptor status and genetic alterations across our patients with MBC BM suggest heterogeneity in disease. Larger studies are needed to further explore MBC BM characteristics and treatment outcomes.

Indexed as

Brain metastasesGeneticsMale breast cancerStereotactic radiosurgery

Identifiers

PMID41163992
PMCPMC12560722

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.